Neuro-Oncology Perspective of Treatment Options in Metastatic Breast Cancer

References

• Goldhirsch A , WinerEP, CoatesASet al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol.24(9), 2206–2223 (2013).
   PubMed Web of Science ®Google Scholar
• Kennecke H , YerushalmiR, WoodsRet al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol.28(20), 3271–3277 (2010).
   PubMed Web of Science ®Google Scholar
• Zagar TM , Van SwearingenAE, Kaidar-PersonO, EwendMG, AndersCK. Multidisciplinary management of breast cancer brain metastases. Oncology30(10), 923–933 (2016).
   PubMed Web of Science ®Google Scholar
• Mounsey LA , DealAM, KeithKCet al. Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies. Clin. Breast Cancer18(1), 29–37 (2018).
   PubMed Web of Science ®Google Scholar
• Morikawa A , JordanL, RoznerRet al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin. Breast Cancer17(1), 23–28 (2017).
   PubMed Web of Science ®Google Scholar
• Patchell RA , TibbsPA, WalshJWet al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med.322(8), 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Vecht CJ , Haaxma-ReicheH, NoordijkEMet al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 33(6), 583–590 (1993).
   PubMed Web of Science ®Google Scholar
• Mintz AH , KestleJ, RathboneMPet al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer78(7), 1470–1476 (1996).
   PubMed Web of Science ®Google Scholar
• Pollock BE , BrownPD, FooteRL, StaffordSL, SchombergPJ. Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J. Neurooncol.61(1), 73–80 (2003).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA , SuhJH. Resectable brain metastases. J. Clin. Oncol.24(8), 1289–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Kamp MA , RappM, BuhnerJet al. Early postoperative magnet resonance tomography after resection of cerebral metastases. Acta Neurochir. (Wien)157(9), 1573–1580 (2015).
   PubMed Web of Science ®Google Scholar
• Kamp MA , FischerI, BuhnerJet al. 5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression. Oncotarget7(41), 66776–66789 (2016).
   PubMedGoogle Scholar
• Ferraro N , BarbariteE, AlbertTRet al. The role of 5-aminolevulinic acid in brain tumor surgery: a systematic review. Neurosurg. Rev.39(4), 545–555 (2016).
   PubMed Web of Science ®Google Scholar
• Soffietti R , AbaciogluU, BaumertBet al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neurooncology19(2), 162–174 (2017).
   PubMed Web of Science ®Google Scholar
• Patel AJ , SukiD, HatibogluMA, RaoVY, FoxBD, SawayaR. Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis. J. Neurosurg.122(5), 1132–1143 (2015).
   PubMed Web of Science ®Google Scholar
• Brastianos PK , CarterSL, SantagataSet al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov.5(11), 1164–1177 (2015).
   PubMed Web of Science ®Google Scholar
• Pentsova EI , ShahRH, TangJet al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J. Clin. Oncol.34(20), 2404–2415 (2016).
   PubMed Web of Science ®Google Scholar
• Morikawa A , PeereboomDM, ThorsheimHRet al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neurooncology17(2), 289–295 (2015).
   PubMed Web of Science ®Google Scholar
• Lippitz B , LindquistC, PaddickI, PetersonD, O’NeillK, BeaneyR. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat. Rev.40(1), 48–59 (2014).
   PubMed Web of Science ®Google Scholar
• Yamamoto M , SerizawaT, ShutoTet al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol.15(4), 387–395 (2014).
   PubMed Web of Science ®Google Scholar
• Andrews DW , ScottCB, SperdutoPWet al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet363(9422), 1665–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhnol J , KuhnolC, VordermarkD. Radiotherapy of brain metastases from breast cancer: treatment results and prognostic factors. Oncol. Lett.11(5), 3223–3227 (2016).
   PubMed Web of Science ®Google Scholar
• Sperduto PW , ShanleyR, LuoXet al. Secondary analysis of RTOG 9508, a Phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1–3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int. J. Radiat. Oncol. Biol. Phys.90(3), 526–531 (2014).
   PubMed Web of Science ®Google Scholar
• Yamamoto M , SerizawaT, HiguchiYet al. A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 study update): irradiation-related complications and long-term maintenance of mini-mental state examination scores. Int. J. Radiat. Oncol. Biol. Phys.99(1), 31–40 (2017).
   PubMed Web of Science ®Google Scholar
• Auchter RM , LamondJP, AlexanderEet al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int. J. Radiat. Oncol. Biol. Phys.35(1), 27–35 (1996).
   PubMed Web of Science ®Google Scholar
• Muacevic A , WowraB, SiefertA, TonnJC, SteigerHJ, KrethFW. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre Phase III trial. J. Neurooncol.87(3), 299–307 (2008).
   PubMed Web of Science ®Google Scholar
• Eaton BR , LariviereMJ, KimSet al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J. Neurooncol.123(1), 103–111 (2015).
   PubMed Web of Science ®Google Scholar
• Mahajan A , AhmedS, McAleerMFet al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, Phase 3 trial. Lancet Oncol.18(8), 1040–1048 (2017).
   PubMed Web of Science ®Google Scholar
• Brown PD , BallmanKV, CerhanJHet al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, Phase 3 trial. Lancet Oncol.18(8), 1049–1060 (2017).
   PubMed Web of Science ®Google Scholar
• Suki D , AbouassiH, PatelAJ, SawayaR, WeinbergJS, GrovesMD. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J. Neurosurg.108(2), 248–257 (2008).
   PubMed Web of Science ®Google Scholar
• Ahn JH , LeeSH, KimSet al. Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J. Neurosurg.116(5), 984–993 (2012).
   PubMed Web of Science ®Google Scholar
• Atalar B , ModlinLA, ChoiCYet al. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int. J. Radiat. Oncol. Biol. Phys.87(4), 713–718 (2013).
   PubMed Web of Science ®Google Scholar
• Johnson MD , AvkshtolV, BaschnagelAMet al. Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery. Int. J. Radiat. Oncol. Biol. Phys.94(3), 537–543 (2016).
   PubMed Web of Science ®Google Scholar
• Asher AL , BurriSH, WigginsWFet al. A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. Int. J. Radiat. Oncol. Biol. Phys.88(4), 899–906 (2014).
   PubMed Web of Science ®Google Scholar
• Patel KR , BurriSH, AsherALet al. Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: a multi-institutional analysis. Neurosurgery79(2), 279–285 (2016).
   PubMed Web of Science ®Google Scholar
• Prabhu RS , PressRH, PatelKRet al. Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: a multi-institutional analysis. Int. J. Radiat. Oncol. Biol. Phys.99(2), 459–467 (2017).
   PubMedGoogle Scholar
• Soffietti R , ChiavazzaC, RudaR. Imaging and clinical end points in brain metastases trials. CNS Oncol.6(4), 243–246 (2017).
   PubMedGoogle Scholar
• Lin NU , LeeEQ, AoyamaHet al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol.16(6), e270–e278 (2015).
   PubMed Web of Science ®Google Scholar
• Chao ST , AhluwaliaMS, BarnettGHet al. Challenges with the diagnosis and treatment of cerebral radiation necrosis. Int. J. Radiat. Oncol. Biol. Phys.87(3), 449–457 (2013).
   PubMed Web of Science ®Google Scholar
• Chuang MT , LiuYS, TsaiYS, ChenYC, WangCK. Differentiating radiation-induced necrosis from recurrent brain tumor using MR perfusion and spectroscopy: a meta-analysis. PLoS ONE11(1), e0141438 (2016).
   PubMed Web of Science ®Google Scholar
• Hatzoglou V , YangTJ, OmuroAet al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neurooncology18(6), 873–880 (2016).
   PubMed Web of Science ®Google Scholar
• Wagner S , LanfermannH, EichnerG, GuflerH. Radiation injury versus malignancy after stereotactic radiosurgery for brain metastases: impact of time-dependent changes in lesion morphology on MRI. Neuro Oncol.19(4), 586–594 (2016).
   Web of Science ®Google Scholar
• Heinzel A , MullerD, Yekta-MichaelSSet al. O-(2–18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost–effectiveness analysis. Neurooncology19(9), 1271–1278 (2017).
   PubMed Web of Science ®Google Scholar
• Minniti G , ScaringiC, BaldoniAet al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int. J. Radiat. Oncol. Biol. Phys.86(2), 285–291 (2013).
   PubMed Web of Science ®Google Scholar
• Mathieu D , KondziolkaD, FlickingerJCet al. Tumor bed radiosurgery after resection of cerebral metastases. Neurosurgery62(4), 817–823; discussion 823–814 (2008).
   PubMed Web of Science ®Google Scholar
• Minniti G , ScaringiC, PaoliniSet al. Single-fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int. J. Radiat. Oncol. Biol. Phys.95(4), 1142–1148 (2016).
   PubMed Web of Science ®Google Scholar
• Boothe D , YoungR, YamadaY, PragerA, ChanT, BealK. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neurooncology15(9), 1257–1263 (2013).
   PubMed Web of Science ®Google Scholar
• Aoyama H , TagoM, KatoNet al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys.68(5), 1388–1395 (2007).
   PubMed Web of Science ®Google Scholar
• Kocher M , SoffiettiR, AbaciogluUet al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J. Clin. Oncol.29(2), 134–141 (2011).
   PubMed Web of Science ®Google Scholar
• Soffietti R , KocherM, AbaciogluUMet al. A European Organisation for Research and Treatment of Cancer Phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J. Clin. Oncol.31(1), 65–72 (2013).
   PubMed Web of Science ®Google Scholar
• Wagner J , MarquartJ, RubyJet al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ360, k668 (2018).
   PubMedGoogle Scholar
• DeAngelis LM , DelattreJY, PosnerJB. Radiation-induced dementia in patients cured of brain metastases. Neurology39(6), 789–796 (1989).
   PubMed Web of Science ®Google Scholar
• Chang EL , WefelJS, HessKRet al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol.10(11), 1037–1044 (2009).
   PubMed Web of Science ®Google Scholar
• Brown PD , JaeckleK, BallmanKVet al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA316(4), 401–409 (2016).
   PubMed Web of Science ®Google Scholar
• Brown PD , PughS, LaackNNet al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neurooncology15(10), 1429–1437 (2013).
   PubMed Web of Science ®Google Scholar
• Rapp SR , CaseLD, PeifferAet al. Donepezil for irradiated brain tumor survivors: a Phase III randomized placebo-controlled clinical trial. J. Clin. Oncol.33(15), 1653–1659 (2015).
   PubMedGoogle Scholar
• Gondi V , TomeWA, MehtaMP. Why avoid the hippocampus? A comprehensive review. Radiother. Oncol.97(3), 370–376 (2010).
   PubMed Web of Science ®Google Scholar
• Gondi V , PughSL, TomeWAet al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a Phase II multi-institutional trial. J. Clin. Oncol.32(34), 3810–3816 (2014).
   PubMed Web of Science ®Google Scholar
• Suh JH . Hippocampal-avoidance whole-brain radiation therapy: a new standard for patients with brain metastases?J. Clin. Oncol.32(34), 3789–3791 (2014).
   PubMed Web of Science ®Google Scholar
• Cortes J , O’ShaughnessyJ, LoeschDet al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet377(9769), 914–923 (2011).
   PubMed Web of Science ®Google Scholar
• Byun KD , AhnSG, BaikHJet al. Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: two case reports. J. Breast Cancer19(2), 214–217 (2016).
   PubMed Web of Science ®Google Scholar
• Cortes J , RugoHS, AwadaAet al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized Phase III BEACON trial. Breast Cancer Res. Treat.165(2), 329–341 (2017).
   PubMed Web of Science ®Google Scholar
• Regina A , DemeuleM, CheCet al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol.155(2), 185–197 (2008).
   PubMed Web of Science ®Google Scholar
• Chamberlain M , SoffiettiR, RaizerJet al. Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro. Oncol.16(9), 1176–1185 (2014).
   PubMed Web of Science ®Google Scholar
• Costa R , CarneiroBA, WainwrightDAet al. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann. Oncol.28(1), 44–56 (2017).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC , BrignoliS. Trastuzumab in CSF. J. Clin. Oncol.18(11), 2349–2351 (2000).
   PubMed Web of Science ®Google Scholar
• Kurihara H , HamadaA, YoshidaMet al. (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res.5, 8 (2015).
   PubMed Web of Science ®Google Scholar
• Lin NU , ProwellT, TanARet al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. J. Clin. Oncol.35(33), 3753–3759 (2017).
   PubMed Web of Science ®Google Scholar
• Jacot W , PonsE, FrenelJSet al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res. Treat.157(2), 307–318 (2016).
   PubMed Web of Science ®Google Scholar
• Oliveira M , BragaS, Passos-CoelhoJL, FonsecaR, OliveiraJ. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res. Treat.127(3), 841–844 (2011).
   PubMed Web of Science ®Google Scholar
• Dumitrescu C , LossignolD. Intrathecal trastuzumab treatment of the neoplastic meningitis due to breast cancer: a case report and review of the literature. Case Rep. Oncol. Med.2013, 154674 (2013).
   PubMedGoogle Scholar
• Martens J , VenuturumilliP, CorbetsL, BestulD. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases. Acta Oncol.52(1), 175–178 (2013).
   PubMed Web of Science ®Google Scholar
• Zagouri F , SergentanisTN, BartschRet al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res. Treat.139(1), 13–22 (2013).
   PubMed Web of Science ®Google Scholar
• Lin NU , DierasV, PaulDet al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res.15(4), 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Bachelot T , RomieuG, CamponeMet al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase 2 study. Lancet. Oncol.14(1), 64–71 (2013).
   PubMed Web of Science ®Google Scholar
• Cameron D , CaseyM, PressMet al. A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat.112(3), 533–543 (2008).
   PubMed Web of Science ®Google Scholar
• Pivot X , ManikhasA, ZurawskiBet al. CEREBEL (EGF111438): a Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol.33(14), 1564–1573 (2015).
   PubMed Web of Science ®Google Scholar
• Krop IE , LinNU, BlackwellKet al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann. Oncol.26(1), 113–119 (2015).
   PubMed Web of Science ®Google Scholar
• Polli JW , HumphreysJE, HarmonKAet al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos.36(4), 695–701 (2008).
   PubMed Web of Science ®Google Scholar
• Taskar KS , RudrarajuV, MittapalliRKet al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res.29(3), 770–781 (2012).
   PubMed Web of Science ®Google Scholar
• Swain SM , ImYH, ImSAet al. Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the Phase III trial CLEOPATRA. Oncologist19(7), 693–701 (2014).
   PubMed Web of Science ®Google Scholar
• Zhao XQ , XieJD, ChenXGet al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol. Pharmacol.82(1), 47–58 (2012).
   PubMed Web of Science ®Google Scholar
• Bose R , KavuriSM, SearlemanACet al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov.3(2), 224–237 (2013).
   PubMed Web of Science ®Google Scholar
• Canonici A , GijsenM, MulloolyMet al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget4(10), 1592–1605 (2013).
   PubMed Web of Science ®Google Scholar
• Freedman RA , GelmanRS, WefelJSet al. Translational Breast Cancer Research Consortium (TBCRC) 022: a Phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol.34(9), 945–952 (2016).
   PubMed Web of Science ®Google Scholar
• Freedman RA , GelmanRS, MeliskoMEet al. TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). J. Clin. Oncol.35(15 Suppl.), 1005–1005 (2017).
   Google Scholar
• Awada A , ColomerR, InoueKet al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol.2(12), 1557–1564 (2016).
   PubMed Web of Science ®Google Scholar
• Moulder SL , BorgesVF, BaetzTet al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin. Cancer Res.23(14), 3529–3536 (2017).
   PubMed Web of Science ®Google Scholar
• Sahebjam S , RhunEL, KulanthaivelPet al. Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. J. Clin. Oncol.34(15 Suppl.), 526–526 (2016).
   Web of Science ®Google Scholar
• Chopra N , TurnerNC. Targeting PIK3CA-mutant advanced breast cancer in the clinical setting. Lancet Oncol.18(7), 842–843 (2017).
   PubMed Web of Science ®Google Scholar
• Robson ME , ImS-A, SenkusEet al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). J. Clin. Oncol.35(18 Suppl.), LBA4–LBA4 (2017).
   Web of Science ®Google Scholar
• Lu YS , ChenTW, LinCHet al. Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin. Cancer Res.21(8), 1851–1858 (2015).
   PubMed Web of Science ®Google Scholar
• Camidge DR , LeeEQ, LinNUet al. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol.19(1), e20–e32 (2018).
   PubMed Web of Science ®Google Scholar
• Martin AM , CagneyDN, CatalanoPJet al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol.3(8), 1069–1077 (2017).
   PubMed Web of Science ®Google Scholar
• Duchnowska R , JassemJ, GoswamiCPet al. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. J. Neurooncol.122(1), 205–216 (2015).
   PubMed Web of Science ®Google Scholar